Document is current
Any future updates will be listed below
-
Authors
Ajani, Jaffer A. https://orcid.org/0000-0001-9946-0629
Wang, Kaijun https://orcid.org/0009-0005-0537-978X
Nikolaidis, Georgios F. https://orcid.org/0000-0001-9008-6896
Coaquira Castro, JeanPierre https://orcid.org/0009-0001-7063-2420
Augusto Novis de Figueiredo, Maximiliano
Sun, Jong-Mu https://orcid.org/0000-0003-1800-5881
Soulanis, Konstantinos
Tasoulas, Anastasios https://orcid.org/0009-0004-3709-639X
Zhan, Lin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03430843 at ClinicalTrials.govDocuments that mention this clinical trial
79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
https://doi.org/10.1136/jitc-2020-sitc2020.0079
Long-term pooled safety analysis of tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.
https://doi.org/10.1200/jco.2024.42.16_suppl.e14617
Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302
https://doi.org/10.1007/s10388-023-01040-w
Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons
https://doi.org/10.1007/s12325-025-03410-5
<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
https://doi.org/10.1200/jco-24-01818
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
https://doi.org/10.1136/jitc-2019-000437
Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC).
https://doi.org/10.1200/jco.2024.42.3_suppl.390
-
Funding
Funding for this research was provided by:
BeOne Medicines Ltd.
- License Information
-
More Information
Article History
Received: 5 August 2025
Accepted: 16 October 2025
First Online: 3 December 2025
Declarations
:
: Kaijun Wang and Lin Zhan are employees of BeOne Medicines. JeanPierre Coaquira Castro was an employee of BeOne Medicines at the time of the study, and is currently an employee at Gilead Science. Georgios F. Nikolaidis, Konstantinos Soulanis, and Anastasios Tasoulas are employees of IQVIA Ltd., a vendor contracted to develop methods, generate statistical models, support statistical analyses, and provide editorial assistance in the development of the manuscript on behalf of BeOne Medicines. Jaffer A. Ajani, Maximiliano Augusto Novis de Figueiredo, and Jong-Mu Sun declare that they have no competing interests.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
: Not applicable.
